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Drs Raju, Darcey, and Neglen add more information about
the important role of venous obstruction to the syndrome of
chronic venous insufficiency (CVI) in patients with deep venous
reflux disease. From my perspective, the most important findings
of this study include: venous stenting improved the rates of healed
ulcers, freedom of ulcer-recurrence rates in legs with healed ulcers
(C5), and freedom from leg dermatitis; venous stenting improved
pain and swelling at 5 years with no differences between non-
thrombotic and post-thrombotic obstructions, limbs with severe vs
moderate reflux, and limbs with axial and segmental reflux; venous
stenting did not result in a deterioration of reflux parameters; and
deep venous reflux can be initially ignored if it is combined with
iliac vein obstruction.
The authors of the current study have been leaders in the area
of iliac venous obstruction treatment, and they have the largest
world experience using venoplasty and stenting. They used large
caliber stents (14-18 mm), covered all lesions without skip areas,
extended stents into the inferior vena cava (IVC) 3 to 5 cm, and
extended stents below the inguinal ligament as necessary. The
patients exhibited advanced chronic venous disease with all having
deep venous reflux, 59% demonstrating severe global reflux, 42%
showing deep axial reflux, and 65% having superficial venous refluxin addition. By intravascular ultrasound (IVUS) scan, the percent
stenosis was 74%, and despite this only 43% demonstrated collat-
erals on venography suggesting that this venographic sign leaves
much to be desired. Only a small percentage of patients required
open valve reconstructions by the authors, a group that has written
extensively on these vein valve procedures in the past. It is surpris-
ing that the results were so good in which only the obstructive
component of the disease was treated. The authors have suggested
that nonthrombotic iliac vein lesions (NIVL) play a pivotal “per-
missive” role in the development of chronic venous insufficiency,
and the current study supports this suggestion.
How can this study be put into context? As the authors
suggest, “a stepwise correction of pathology may be applied using
initially minimally invasive techniques.” One cannot comment on
saphenous vein ablation related to iliac vein stenting from the
current study as limbs with concurrent saphenous ablation per-
formed along with stenting were excluded, as were limbs with
reflux confined only to the superficial venous system.However, the
current study suggests that if iliac venous obstruction is part of the
pathophysiology of CVI, iliac venous stenting should be per-
formed as first-line therapy.
